Fate Therapeutics, Inc.
FATE · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $13,631 | $63,533 | $96,300 | $55,846 |
| % Growth | -78.5% | -34% | 72.4% | – |
| Cost of Goods Sold | $0 | $157,187 | $13,758 | $5,850 |
| Gross Profit | $13,631 | -$93,654 | $82,542 | $49,996 |
| % Margin | 100% | -147.4% | 85.7% | 89.5% |
| R&D Expenses | $135,001 | $172,596 | $320,454 | $215,519 |
| G&A Expenses | $74,169 | $81,448 | $84,232 | $57,321 |
| SG&A Expenses | $74,169 | $96,857 | $84,232 | $57,321 |
| Sales & Mktg Exp. | $0 | $15,409 | $0 | $0 |
| Other Operating Expenses | $14,737 | -$172,596 | -$13,758 | -$5,850 |
| Operating Expenses | $223,907 | $96,857 | $390,928 | $266,990 |
| Operating Income | -$210,276 | -$190,511 | -$308,386 | -$216,994 |
| % Margin | -1,542.6% | -299.9% | -320.2% | -388.6% |
| Other Income/Exp. Net | $24,014 | $29,583 | $26,665 | $4,843 |
| Pre-Tax Income | -$186,262 | -$160,928 | -$281,721 | -$212,151 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$186,262 | -$160,928 | -$281,721 | -$212,151 |
| % Margin | -1,366.5% | -253.3% | -292.5% | -379.9% |
| EPS | -1.64 | -1.64 | -2.91 | -2.24 |
| % Growth | 0% | 43.6% | -29.9% | – |
| EPS Diluted | -1.64 | -1.64 | -2.91 | -2.24 |
| Weighted Avg Shares Out | 113,685 | 98,411 | 96,826 | 94,747 |
| Weighted Avg Shares Out Dil | 113,685 | 98,411 | 96,826 | 94,747 |
| Supplemental Information | – | – | – | – |
| Interest Income | $17,288 | $17,186 | $5,842 | $1,309 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $18,962 | $18,282 | $13,758 | $5,850 |
| EBITDA | -$176,577 | -$172,229 | -$294,628 | -$211,144 |
| % Margin | -1,295.4% | -271.1% | -305.9% | -378.1% |